Maven Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Maven Securities’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.03M	Buy	+19,147	New	+$2.59M	0.06%	201
2025 Q4	–	Sell	-13,840	Closed	-$1.39M	–	563
2025 Q3	$1.39M	Sell	13,840 -28,277	-67%	-$2.55M	0.03%	332
2025 Q2	$3.49M	Buy	42,117 +23,011	+120%	+$1.84M	0.08%	223
2025 Q1	$1.55M	Buy	19,106 +8,214	+75%	+$734K	0.05%	333
2024 Q4	$981K	Buy	10,892 +828	+8%	+$80.2K	0.02%	421
2024 Q3	$994K	Sell	10,064 -77,095	-88%	-$7.57M	0.02%	501
2024 Q2	$8.08M	Buy	87,159 +37,638	+76%	+$3.37M	0.18%	115
2024 Q1	$4.7M	Buy	49,521 +18,121	+58%	+$1.68M	0.28%	45
2023 Q4	$2.8M	Buy	31,400 +275	+0.9%	+$20.4K	0.06%	242
2023 Q3	$2.27M	Sell	31,125 -8,410	-21%	-$672K	0.03%	369
2023 Q2	$3.29M	Buy	+39,535	New	+$3.31M	0.05%	185
2022 Q4	–	Sell	-10,539	Closed	-$836K	–	1155
2022 Q3	$836K	Buy	+10,539	New	+$889K	0.02%	612
2022 Q2	–	Sell	-4,292	Closed	-$386K	–	1142
2022 Q1	$386K	Buy	+4,292	New	+$396K	0.01%	617
2021 Q3	–	Sell	-6,200	Closed	-$851K	–	1295
2021 Q2	$851K	Sell	6,200 -11,678	-65%	-$1.54M	0.03%	488
2021 Q1	$2.4M	Buy	17,878 +12,981	+265%	+$1.94M	0.11%	186
2020 Q4	$706K	Sell	4,897 -15,676	-76%	-$2.01M	0.07%	300
2020 Q3	$2.32M	Buy	+20,573	New	+$2.31M	0.19%	117
2018 Q4	–	Sell	-7,300	Closed	-$703K	–	175
2018 Q3	$703K	Buy	+7,300	New	+$708K	0.26%	85
2017 Q4	–	Sell	-2,500	Closed	-$215K	–	59
2017 Q3	$215K	Buy	+2,500	New	+$200K	0.11%	34
2017 Q1	–	Sell	-2,353	Closed	-$140K	–	65
2016 Q4	$140K	Buy	+2,353	New	+$145K	0.13%	29

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Maven Securities's XBI Position: Q2 2026 in Review

Maven Securities opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 19,147 shares worth $3.03M. The stake represents 0.06% of the portfolio and ranks #201 among its holdings. This is a return to the name: Maven Securities previously reported a position in XBI as recently as Q3 2025.

Maven Securities first reported a position in XBI in Q4 2016 and has held it in 20 quarters since. The position peaked at $8.08M in Q2 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Maven Securities held 19,147 shares of State Street SPDR S&P Biotech ETF worth $3.03M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Maven Securities position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.06% of Maven Securities's portfolio in Q2 2026, its #201 holding.
Maven Securities first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 20 quarters since.
Maven Securities's State Street SPDR S&P Biotech ETF position peaked at $8.08M in Q2 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.